Kineta Announces KVA12123 And Anti-CD27 Agonist Antibody Abstracts Accepted For Poster Presentations At Society For Immunotherapy Of Cancer 2023; Shares Halted On Circuit Breaker To The Upside
Portfolio Pulse from Benzinga Newsdesk
Kineta, Inc. (NASDAQ:KA) announced that two abstracts on its immuno-oncology therapies have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The presentations will include new clinical data on KVA12123, Kineta's VISTA blocking immunotherapy, and new preclinical data on its anti-CD27 agonist antibody program. Following the announcement, Kineta's shares were halted on a circuit breaker to the upside.
October 12, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kineta's announcement of the acceptance of two abstracts for presentation at the SITC 2023 could potentially boost investor confidence in the company's immuno-oncology therapies, leading to a positive impact on its stock price.
The acceptance of Kineta's abstracts for presentation at a prestigious conference like SITC indicates recognition of the company's work in the field of immuno-oncology. This could potentially boost investor confidence in the company's therapies, leading to a positive impact on its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100